Skip to content
Uncategorized

House Passes 2026 Farm Bill With Intoxicating Hemp Ban Intact in 224-200 Vote

andrew
3 min read

House Passes 2026 Farm Bill With Intoxicating Hemp Ban Intact in 224-200 Vote

The bill separates industrial hemp from cannabinoid products, loosening rules for fiber farmers while tightening the regulatory path for CBD and THC brands.

By CBDWorldNews Editorial Staff | May 5, 2026

The U.S. House of Representatives voted 224-200 on April 30 to pass the Farm, Food, and National Security Act of 2026, sending a bill to the Senate that preserves the controversial redefinition of hemp enacted last November. The measure formally splits “industrial hemp” for fiber and grain from all cannabinoid-linked production, pushing CBD and THC products into a stricter regulatory lane.

What the Bill Does

The 2026 Farm Bill replaces the delta-9 THC threshold from the 2018 version with a total THC standard. Under the new definition, hemp is cannabis sativa L. with a total THC concentration — including THCA and delta-8 THC — of no more than 0.3% on a dry weight basis. Finished consumer products face a ceiling of 0.4 milligrams of total THC per container.

The U.S. Hemp Roundtable estimates this standard would make approximately 95% of existing hemp-derived cannabinoid products federally unlawful once it takes effect in November.

For industrial hemp growers focused on fiber, grain, and seed, the bill delivers relief. It allows the USDA to reduce or eliminate testing requirements and background checks, and extends protections to state and tribal government hemp programs. This two-track approach acknowledges that the farmer growing hemp for building materials faces different regulatory needs than the company selling THC seltzers.

The Numbers at Stake

Industry groups have painted a stark picture of the economic fallout if the cannabinoid provisions take effect without modification. According to data cited during floor debate:

  • Over 300,000 American jobs tied to hemp-derived cannabinoid products
  • $28.4 billion in annual market activity
  • $1.5 billion in aggregate state tax revenue
  • A $1.3 billion hemp beverage sector that emerged entirely under the 2018 Farm Bill framework

“We are looking at an industry that grew from nothing to $28 billion in six years, and Congress is preparing to pull the rug out.” — Industry representative during House Agriculture Committee markup

Senate Outlook

The bill now moves to the Senate, where the Agriculture Committee has signaled interest in a companion approach but has not committed to the same timeline. Several senators from hemp-producing states have expressed concern about the November effective date, and the Hemp Planting Predictability Act — introduced in January — would push implementation to November 2028 to allow a transitional regulatory framework.

Political observers expect the Senate to attach amendments addressing the CBD market specifically, potentially creating a regulatory pathway for certain low-THC products that would otherwise be swept up in the ban.

What This Means for CBD Brands

Companies selling CBD oils, tinctures, and topicals face a narrowing window. Products that contain any detectable THCA — which includes most full-spectrum extracts — will need reformulation or will become non-compliant by November unless the Senate modifies the timeline.

Brands focused on CBD isolate and broad-spectrum products with verified zero-THC formulations may find themselves better positioned, though the 0.4mg per-container cap on total THC creates challenges even for products that currently test as “THC-free” under less sensitive methods.

For consumers, the practical impact depends on Senate action over the summer. Current CBD products remain legal to purchase and possess. The changes affect manufacturing and retail sales at the federal level, and verified lab testing will become more important than ever for determining which products meet the new standard.

The Larger Picture

The vote marks the clearest signal yet that Congress views the unregulated growth of intoxicating hemp products as a public-health issue requiring federal action. Whether the final legislation balances that concern against the economic interests of a $28 billion industry will depend on negotiations that could extend through the summer recess.

These statements have not been evaluated by the Food and Drug Administration. CBD products are not intended to diagnose, treat, cure, or prevent any disease.

Related Stories